Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026850 (
muscular dystrophy
)
5,870
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The genetic abnormality in myotonic
muscular dystrophy
, multiple CTG repeats lie upstream of a gene that encodes a novel protein kinase, myotonic dystrophy protein kinase (DMPK).
Phospholemman
(
PLM
), a major membrane substrate for phosphorylation by protein kinases A and C, induces Cl currents (I(Cl(
PLM
))) when expressed in Xenopus oocytes. To test the idea that
PLM
is a substrate for DMPK, we measured in vitro phosphorylation of purified
PLM
by DMPK. To assess the functional effects of
PLM
phosphorylation we compared I(Cl(
PLM
)) in Xenopus oocytes expressing
PLM
alone to currents in oocytes co-expressing DMPK, and examined the effect of DMPK on oocyte membrane
PLM
expression. We found that
PLM
is indeed a good substrate for DMPK in vitro. Co-expression of DMPK with
PLM
in oocytes resulted in a reduction in I(Cl(
PLM
)). This was most likely a specific effect of phosphorylation of
PLM
by DMPK, as the effect was not present in oocytes expressing a phos(-)
PLM
mutant in which all potential phosphorylation had been disabled by Ser --> Ala substitution. The biophysical characteristics of I(Cl(
PLM
)) were not changed by DMPK or by the phos(-) mutation. Co-expression of DMPK reduced the expression of
PLM
in oocyte membranes, suggesting a possible mechanism for the observed reduction in I(Cl(
PLM
)) amplitude. These data show that
PLM
is a substrate for phosphorylation by DMPK and provide functional evidence for modulation of
PLM
function by phosphorylation.
...
PMID:Phospholemman is a substrate for myotonic dystrophy protein kinase. 1081 36